| Silvestro J Lijoi, DO | |
|
1114 N Main St, Summerville, SC 29483-7326 | |
| (843) 212-8070 | |
| (843) 212-8071 |
| Full Name | Silvestro J Lijoi |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 28 Years |
| Location | 1114 N Main St, Summerville, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780679118 | NPI | - | NPPES |
| 1545 | Other | SC | SC MEDICAL LICENSE |
| 5905797 | Medicaid | NC | |
| 015450 | Medicaid | SC | |
| 010069777 | Medicaid | VA |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Onespotmd Primary And Urgent Care Pllc | 4183036650 | 4 |
News Archive
A machine-learning model can identify patients at risk of a rare cardiomyopathy, according to a study published in Nature Communications.
Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.
We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.
A recent Special Issue of Business Horizons (www.elsevier.com/locate/bushor), the journal of the Kelley School of Business, Indiana University, and published by Elsevier, addresses issues central to healthcare and life sciences. Healthcare reform, for example, has been at the center of U.S. political debate in recent years with renewed attempts to gain bipartisan support from Congress for passage of a national system of health insurance coverage.
› Verified 2 days ago
| Entity Name | Wake Forest University Health Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803032 PECOS PAC ID: 4486564952 Enrollment ID: O20031105000436 |
News Archive
A machine-learning model can identify patients at risk of a rare cardiomyopathy, according to a study published in Nature Communications.
Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.
We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.
A recent Special Issue of Business Horizons (www.elsevier.com/locate/bushor), the journal of the Kelley School of Business, Indiana University, and published by Elsevier, addresses issues central to healthcare and life sciences. Healthcare reform, for example, has been at the center of U.S. political debate in recent years with renewed attempts to gain bipartisan support from Congress for passage of a national system of health insurance coverage.
› Verified 2 days ago
| Entity Name | Dlp Central Carolina Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396101689 PECOS PAC ID: 6709180656 Enrollment ID: O20160212001472 |
News Archive
A machine-learning model can identify patients at risk of a rare cardiomyopathy, according to a study published in Nature Communications.
Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.
We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.
A recent Special Issue of Business Horizons (www.elsevier.com/locate/bushor), the journal of the Kelley School of Business, Indiana University, and published by Elsevier, addresses issues central to healthcare and life sciences. Healthcare reform, for example, has been at the center of U.S. political debate in recent years with renewed attempts to gain bipartisan support from Congress for passage of a national system of health insurance coverage.
› Verified 2 days ago
| Entity Name | Afc Urgent Care And Family Care Of Wnc Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679066658 PECOS PAC ID: 2567713332 Enrollment ID: O20180919000143 |
News Archive
A machine-learning model can identify patients at risk of a rare cardiomyopathy, according to a study published in Nature Communications.
Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.
We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.
A recent Special Issue of Business Horizons (www.elsevier.com/locate/bushor), the journal of the Kelley School of Business, Indiana University, and published by Elsevier, addresses issues central to healthcare and life sciences. Healthcare reform, for example, has been at the center of U.S. political debate in recent years with renewed attempts to gain bipartisan support from Congress for passage of a national system of health insurance coverage.
› Verified 2 days ago
| Entity Name | Onespotmd Primary And Urgent Care Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164021051 PECOS PAC ID: 4183036650 Enrollment ID: O20201208001255 |
News Archive
A machine-learning model can identify patients at risk of a rare cardiomyopathy, according to a study published in Nature Communications.
Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.
We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.
A recent Special Issue of Business Horizons (www.elsevier.com/locate/bushor), the journal of the Kelley School of Business, Indiana University, and published by Elsevier, addresses issues central to healthcare and life sciences. Healthcare reform, for example, has been at the center of U.S. political debate in recent years with renewed attempts to gain bipartisan support from Congress for passage of a national system of health insurance coverage.
› Verified 2 days ago
| Entity Name | Onespotmd Primary And Urgent Care Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750001749 PECOS PAC ID: 4183036650 Enrollment ID: O20221011001266 |
News Archive
A machine-learning model can identify patients at risk of a rare cardiomyopathy, according to a study published in Nature Communications.
Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.
We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.
A recent Special Issue of Business Horizons (www.elsevier.com/locate/bushor), the journal of the Kelley School of Business, Indiana University, and published by Elsevier, addresses issues central to healthcare and life sciences. Healthcare reform, for example, has been at the center of U.S. political debate in recent years with renewed attempts to gain bipartisan support from Congress for passage of a national system of health insurance coverage.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Silvestro J Lijoi, DO Po Box 751649, Charlotte, NC 28275-1649 Ph: () - | Silvestro J Lijoi, DO 1114 N Main St, Summerville, SC 29483-7326 Ph: (843) 212-8070 |
News Archive
A machine-learning model can identify patients at risk of a rare cardiomyopathy, according to a study published in Nature Communications.
Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.
We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.
A recent Special Issue of Business Horizons (www.elsevier.com/locate/bushor), the journal of the Kelley School of Business, Indiana University, and published by Elsevier, addresses issues central to healthcare and life sciences. Healthcare reform, for example, has been at the center of U.S. political debate in recent years with renewed attempts to gain bipartisan support from Congress for passage of a national system of health insurance coverage.
› Verified 2 days ago
Dr. David Paul Smith, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 133 E 1st North St, Suite 2 Magnolia Square, Summerville, SC 29483 Phone: 843-871-1800 Fax: 843-871-5121 | |
Dr. Suzann Hutto Weathers, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 87 Springview Ln, Summerville, SC 29485 Phone: 843-876-7979 | |
Anthony Joel Yuen, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1112 N Main St, Summerville, SC 29483 Phone: 843-212-8080 Fax: 843-212-8081 | |
Dr. Merritt Stanley Huber Iii, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 1st Avenue, Summerville, SC 29486 Phone: 843-876-7930 | |
Dr. Amy Carol Forren, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1724 State Rd Unit 6b, Summerville, SC 29486 Phone: 843-606-7100 | |
Dana L Simpson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 679 Orangeburg Rd, Suite F, Summerville, SC 29483 Phone: 843-261-2600 Fax: 888-839-6837 | |
Dr. Walter David Leventhal, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 299 Midland Pkwy # A, Summerville, SC 29485 Phone: 843-875-7901 Fax: 843-832-2038 |